Clarus Wealth Advisors Purchases 216 Shares of Johnson & Johnson (NYSE:JNJ)

Clarus Wealth Advisors boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,367 shares of the company’s stock after purchasing an additional 216 shares during the period. Clarus Wealth Advisors’ holdings in Johnson & Johnson were worth $306,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of JNJ. Phocas Financial Corp. grew its holdings in Johnson & Johnson by 999,928.6% during the 2nd quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $1,743,000 after purchasing an additional 125,161,066 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in Johnson & Johnson by 5,447.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock valued at $2,357,266,000 after purchasing an additional 16,619,550 shares during the last quarter. Thoroughbred Financial Services LLC grew its holdings in Johnson & Johnson by 14,147.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after purchasing an additional 3,986,071 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Johnson & Johnson by 145.5% during the 2nd quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock valued at $604,637,000 after purchasing an additional 2,572,695 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Johnson & Johnson by 11.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock valued at $2,895,870,000 after purchasing an additional 2,204,757 shares during the last quarter. Institutional investors own 72.01% of the company’s stock.

JNJ has been the topic of several analyst reports. Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Friday. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Goldman Sachs Group set a $169.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Raymond James cut their price target on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a report on Wednesday, July 17th. Finally, Credit Suisse Group set a $156.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $151.00.

Johnson & Johnson stock opened at $131.33 on Friday. The stock has a market cap of $346.60 billion, a price-to-earnings ratio of 16.06, a price-to-earnings-growth ratio of 2.22 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The firm has a 50-day moving average of $129.92 and a two-hundred day moving average of $134.97.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.10 EPS. Research analysts expect that Johnson & Johnson will post 8.59 earnings per share for the current year.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Why is the conference call important?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.